The cost-effectiveness of guideline-recommended treatments for osteoarthritis: A systematic review
Osteoarthritis and Cartilage · 2025-11 · 33 (11) · 1274-1292
DOI: 10.1016/j.joca.2025.04.003 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Osteoarthritis and Cartilage, 2025-11. Verfasst von Stephanie Mathieson und 15 weiteren Autor:innen. Beteiligte Einrichtung: Sydney Musculoskeletal Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. Electronic address: stephanie.mathieson@s…. Hauptthemen laut MEDLINE: Osteoarthritis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 148 Literaturangaben. Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
OBJECTIVE: To critically appraise the literature on the cost-effectiveness of guideline-recommended treatments for osteoarthritis (OA). DESIGN: Electronic databases were searched for studies that provided incremental cost-effectiveness ratios (ICER) for treatments recommended by key international guidelines to manage OA in adults. Treatments were grouped as lifestyle and rehabilitative therapies, pharmacological, injection, or surgical. Primary outcome was ICERs, converted to 2023 US dollars for comparability across studies. Risk of bias was assessed using the Consensus on Health Economic Criteria checklist for trials and the Drummond checklist for modelling studies. Studies were deemed cost-effective based on established country-specific thresholds per quality-adjusted life-year. RESULTS: There were 110 studies that included 33 lifestyle and rehabilitative therapies, 25 pharmacological, 11 injection and 42 surgical studies. Most studies (95%) were conducted in high-income countries. Time horizons varied from 8 weeks to a lifetime. Risk of bias domains were frequently scored poorly related to cost methods. Overall, the cost-effectiveness of lifestyle and rehabilitative therapies and non-steroidal anti-inflammatory drugs (NSAIDs) was mixed. Hyaluronic acid injection was cost-effective in knee OA compared to placebo, usual care and paracetamol but not to corticosteroid injections and NSAIDs. Total hip or knee replacement was cost-effective compared to usual care or no surgery, with early access to replacement cost-effective compared to delaying surgery. CONCLUSIONS: There was a diversity of analytical perspectives and clinical heterogeneity of interventions. Policymakers should consider their local context when deciding clinical care and resource allocation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sydney Musculoskeletal Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. Electronic address: stephanie.mathieson@sydney.edu.au.
- Sydney Musculoskeletal Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Institute for Musculoskeletal Health, Sydney Local Health District, Sydney, New South Wales, Australia. Electro…
- Sydney Musculoskeletal Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Department of Rheumatology, Royal North Shore Hospital, St Leonards, New South Wales, Australia. Electronic add…
- School of Health Sciences, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia; Centre for Pain IMPACT, Neuroscience Research Australia, Sydney, Australia; Pain Management and Research Centr…
- Discipline of Health Services Management, School of Public Health, Faculty of Health, University of Technology, Sydney, Australia. Electronic address: Emily.Callander@uts.edu.au.
- Sydney Musculoskeletal Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Kolling Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. Electronic addr…
Förderung
- National Health and Medical Research Council
Zitieren
APA
Mathieson, S., Ferreira, G., Jones, C. M. P., Eyles, J., Bowden, J. L., Sharma, S., Callander, E., Hunter, D., Ackerman, I. N., Keefe, F., Ferreira, M. L., March, L., Briggs, A. M., Sit, R. W., Thirumaran, A. J., & Losina, E. (2025). The cost-effectiveness of guideline-recommended treatments for osteoarthritis: A systematic review. Osteoarthritis and Cartilage, 33(11), 1274-1292. https://doi.org/10.1016/j.joca.2025.04.003
Vancouver
Mathieson S, Ferreira G, Jones CMP, Eyles J, Bowden JL, Sharma S, et al. The cost-effectiveness of guideline-recommended treatments for osteoarthritis: A systematic review. Osteoarthritis and Cartilage. 2025;33(11):1274-1292. doi:10.1016/j.joca.2025.04.003
BibTeX
@article{Mathieson2025,
author = {Mathieson, Stephanie and Ferreira, Giovanni and Jones, Caitlin M P and Eyles, Jillian and Bowden, Jocelyn L and Sharma, Saurab and Callander, Emily and Hunter, David and Ackerman, Ilana N and Keefe, Francis and Ferreira, Manuela L and March, Lyn and Briggs, Andrew M and Sit, Regina Ws and Thirumaran, Aricia Jieqi and Losina, Elena},
title = {The cost-effectiveness of guideline-recommended treatments for osteoarthritis: A systematic review},
journal = {Osteoarthritis and Cartilage},
year = {2025},
volume = {33},
number = {11},
pages = {1274--1292},
doi = {10.1016/j.joca.2025.04.003}
}
EUVIMED